The prevalence of hepatitis C virus (HCV) infection amongst patients with chronic kidney disease (CKD) and end-stage renal disease exceeds that of the general population. In addition to predisposing to the development of cirrhosis and hepatocellular carcinoma, infection with HCV has been associated with extra-hepatic complications including CKD, proteinuria, glomerulonephritis, cryoglobulinemia, increased cardiovascular risk, insulin resistance, and lymphoma. With these associated morbidities, infection with HCV is not unexpectedly accompanied by an increase in mortality in the general population as well as in patients with kidney disease. Advances in the understanding of the HCV genome have resulted in the development of direct-acting antiviral agents that can achieve much higher sustained virologic response rates than previous interferon-based protocols. The direct acting antivirals have either primarily hepatic or renal metabolism and excretion pathways. This information is particularly relevant when considering treatment in patients with reduced kidney function. In this context, some of these agents are not recommended for use in patients with a glomerular filtration rate < 30 mL/min per 1.73 m 2 .
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There are now Food and Drug Administration approved direct acting antiviral agents for the treatment of patients with kidney disease and reduced function. These agents have been demonstrated to be effective with sustained viral response rates comparable to the general population with good safety profiles. A disease that was only recently considered to be very challenging to treat in patients with kidney dysfunction is now curable with these medications.
INTRODUCTION
Hepatitis C virus (HCV) infection is a recognized public health concern with global implications that affects app roximately 170 million individuals worldwide [14] . Infection with HCV is associated with an increased morbidity and mortality secondary to hepatic injury and associated complications [4] . The infection, however, can also affect other organs with significant extrahepatic manifestations ( Figure 1 ). Most noteworthy of these include insulin resistance, cryoglobulinemic vasculitis, sicca syndrome, neurocognitive dysfunction, Bcell nonHodgkin lymphoma and an increase in cardiovascular adverse events [511] . On note, patients with HCV infection also have an in creased incidence of proteinuria and chronic kidney disease (CKD) [5] , often in the setting of essential mixed cryoglobulinemia or "idiopathic" membranoproliferative glomerulonephritis [5, 9, 12] . Furthermore, it has also been well established that patients with end stage renal disease (ESRD) have an even higher prevalence of HCV infection that is likely a consequence of greater blood product exposure and patienttopatient transmission of disease within the dialysis clinics due to breakdowns in universal precautions [12, 13] . This review will summarize the most recent data and treatment options recommended for HCVinfected patients with kidney disease. A population of patients that for years had extremely limited options for therapy can now be successfully and safely treated for eradication of HCV.
HCV AND THE KIDNEY

HCV-related glomerulonephritis with or without cryoglobulinemia
The HCV has an unusual tropism for B lymphocytes through linkage of envelope protein 2 and the CD81 molecule on the B cell. B cell activation can result in expansion of malignant cell lines or the production of unique antibodies that are of the IgM isotype and possess rheumatoid factor like activity [1416] . As a con sequence of these events, clinical syndromes including mixed cryoglobulinemia, lymphoproliferative disorders and glomerulonephritis with distinct histological patterns including membranous or membranoproliferative glome rulonephritis can be seen [5, 6, 17, 18] . Of note, coinfected HIV/HCV patients have an increased mortality and an overall worse prognosis [19, 20] . The glomerular diseases commonly associated with HCV infection are a consequence of the formation of circulating immune complexes that become trapped in the glomerular basement membrane. The clinical expression of this process can occur through type 2 mixed cryoglobulinemia with resulting type 1 mem branoproliferative glomerulonephritis (GN), mesangial proliferative and focal proliferative GN, IgA nephropathy, membranous GN and polyarteritis nodosa [6, 14, 18] .
Typically, the patient that develops cryoglobulinemia has been infected with HCV for many years. These patients may present with a skin rash (palpable purpura), polyneuropathy, multiorgan vasculitis, hypertension and the nephritic syndrome [14] . Suppression of viral replication is necessary to in terrupt immunecomplex production and subsequent injury to the kidney. The VASCUVALDIC study described the use of sofosbuvir and ribavirin in 24 patients with HCVvasculitis syndrome and cryoglobulinemia. Patients were treated with directacting antiviral agents (DAAs) for 24 wk and achieved a sustained viral response at week 12 (SVR12) of 74% with minimal side effects [21] . The less common presentation of an active vasculitic syndrome as part of the cryoglobulinemic syndrome requires a more aggressive treatment strategy targeted at the ongoing endothelial inflammatory process. Options include high dose corticosteroids, rituximab and therapeutic plasma exchange in addition to appropriate DAA therapy to eradicate viral replication [2124] .
Hepatitis C and CKD
HCV infection is highly prevalent in CKD patients [5] and
HCVinfected patients have an increased risk for the development of CKD and proteinuria [5, 25, 26] . Furthermore, emerging data suggests that the rate of CKD progression to ESRD is greater when compared to noninfected patients [2631] . In this context, HCVinfected patients with CKD stages Ⅰ (GFR > 90 mL/min per 1.73 m and Ⅴ (GFR < 15 mL/min per 1.73 m 2 ) will require a more individualized approach depending on the renal replacement therapy options being considered. The major decision point in this context is whether treatment should be recommended before or after kidney transplantation. Patients with a living kidney donor should be treated to achieve a SVR prior to transplantation. For the patient that is going to receive a deceased donor kidney the options may include delaying antiviral treatment in order to receive a kidney from an antiHCV positive donor with the initiation of DAA treatment post transplantation. Alternatively, the patient could be treated pretransplant and then transplanted with a kidney from an antiHCV negative donor. Since not all centers currently accept kidneys from antiHCV positive donors, this option is not available for all patients. Initial reports have demon strated that accepting a kidney from a positive donor is associated with substantially shortened waiting time on the deceased donor waiting list in the United States [3234] . Recent studies have demonstrated the safety and efficacy of DAAs in the kidney transplant recipient, with sustained viral response rates equal to that obtained in the general population with minimal side effects [3537] .
HCV in the ESRD patient
It is estimated that 5%10% of the United States dialysis population is infected with HCV [38] . Many studies have demonstrated that HCV infection is associated with an increased risk of mortality and worse clinical outcomes in ESRD patients [3943] . In a metaanalysis of ESRD patients, Fabrizi et al [41] found that HCV infection was associated with a relative risk of mortality of 1.35 (95%CI: 1.251.47). The increased morbidity and mortality associated with HCV infection emphasizes the systemic impact of this disease which can manifest with multiple extrahepatic manifestations and complications [5, 40] . In this context, an increased cardiovascular risk attributable to HCV infection has been demonstrated in the ESRD patient [40] . In a recent update from the Dialysis Options and Practice Patterns Study data, it was concluded that HCV infection in ESRD patients was associated with an increased risk of death and hospitalization, anemia and worse quality of life scores for physical function, pain, vitality and mental health [44] . Relevant to any discussion on the associated risks accompanying HCV infection is whether successful treatment delivers a positive impact on outcomes. In this context, Hsu et al [45] reported that IFNbased therapy increased survival in HCVin fected ESRD patients. In another report, ESRD patients receiving IFN plus ribavirin obtained improved renal and cardiovascular outcomes compared to those who were untreated [46] . Prospective studies in ESRD patients will be necessary to determine if viral eradication alters the long term outcome of this challenging population of patients with multiple comorbidities.
HCV and kidney transplantation
Kidney transplantation is associated with an increase in long term survival for ESRD patients with HCV infection [47, 48] . This was clearly demonstrated in a longitudinal cohort study in which there was a decreased risk of death post transplantation for the HCVinfected kidney transplant recipients when compared to those remaining on the waiting list [49] . This survival benefit was largely the result of a decrease in cardiovascular events within the first year posttransplant [50] . HCV infection has been linked to several extra hepatic manifestations that combine to increase morbidity and mortality after kidney transplantation [51] . It has been well established that HCV is the primary cause of liver disease in kidney allograft recipients [52] and these patients express an increased risk of insulin re sistance and diabetes mellitus [5358] . Furthermore, HCV infected kidney recipients have a higher probability of developing transplant glomerulopathy [59] and recurrent membranoproliferative glomerulonephritis secondary to immunecomplex injury to the renal allograft [60, 61] .
DIRECT ACTING ANTIVIRAL TREATMENT OPTIONS IN PATIENTS WITH CKD AND POST KIDNEY TRANSPLANT
The availability of DAAs with high SVR rates and favorable adverse event profiles allowed for the study of these drugs in patients with kidney disease, a group that had been excluded from of all the large pivotal trials. Emerging data are now demonstrating an excellent safety and efficacy profile in this patient population (Tables 1 and  2 ). The HCVTARGET is a realworld study that collects data on the use of sofosbuvirbased regimens in HCV infected patients. A total of 73 patients with a GFR ≤ 45 mL/min per 1.73 m 2 (n = 18 with GFR ≤ 30 mL/min per 1.73 m 2 and n = 5 on hemodialysis) were included in the analysis [62] . The SVR rate was 83% in patients with GFR of anemia, worsening kidney function and increased adverse events irrespective of the use of ribavirin [62] . Two open label treatment studies with simeprevir and dose adjusted sofosbuvir exhibited high rates of SVR with a low incidence of adverse events in patients with advanced CKD and ESRD [63, 64] . The RUBYI trial evaluated the 3D regimen [ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus dasabuvir (DSV)] in patients with advanced CKD (stages 4/5) and on dialysis. SVR rates were 90% for patients with HCV genotype (GT) 1 with minimal side effects except for the patients with genotype 1a who received ribavirin as part of the protocol [65] . This group had more anemia events and required erythropoietin dose adjustments. Grazoprevir and elbasvir were studied in HCVinfected GT 1 patients with advanced CKD and ESRD in the CSURFER trial. Sustained viral response rates of 99% were reported with a minimal adverse events profile [66] . The RUBYI Cohort 2 study included patients with stage F4 fibrosis and GT 1a who were treated for 24 wk with the 3D regimen plus ribavirin. SVR24 rates of 89% were reported for this cohort with minimal side effects [67] . The RUBYⅡ study evaluated the use of the 3D regimen in CKD 4 and 5 patients with HCV GT 1a (n = 13) infection without the addition of ribavirin. Genotype 4 patients received OBV/PTV/r without DSV (n = 5). Modified intention to treat (mITT) SVR12 rates of 100% were obtained in both groups [68] . Finally, a recent report described the use of glecaprevir (NS3/4A inhibitor) and pibrentasvir (NS5A inhibitor) in patients with advance kidney disease and HCV genotype 16 infection (n = 104). In this trial, patients with a GFR < 30 mL/min per 1.73 m 2 (n = 13 with GFR 1529 mL/min per 1.73 m 2 , n = 6 with stage 5 CKD and n = 85 on hemodialysis) obtained a 98% ITT SVR12 with no serious adverse events [69] and no viral relapses.
IFNbased protocols have not been recommended after kidney transplantation due to an unacceptably high incidence of rejection events. In contrast, DAA use in kidney transplant recipients has been shown to be safe and effective with minimal side effects [3437] . Caution to avoid drugdrug interactions related to different drug metabolism/interactions (Table 1) is necessary in addition to high vigilance to maintain therapeutic calcineurin inhibitor levels as HCV viremia is suppressed [34, 37] . The availability of DAA agents has dramatically changed the way HCVinfected patients with CKD and ESRD can be managed. While providing outstanding results, these excellent outcomes raise new questions as to which patients should be treated and when is the best time to initiate therapy. Further studies will be 
